Jabara Refat, Gadesam Radhika, Pendyala Lakshmana, Chronos Nicolas, Crisco Larry V, King Spencer B, Chen Jack P
Saint Joseph's Cardiovascular Research Institute, Saint Joseph's Hospital of Atlanta, Atlanta, GA 30342, USA.
Am Heart J. 2008 Dec;156(6):1141-6. doi: 10.1016/j.ahj.2008.07.018. Epub 2008 Oct 9.
Although the safety and cost-effectiveness of same-day discharge after uncomplicated transradial percutaneous coronary intervention (TR-PCI) is well established in Europe and Asia, such data are not available for US patients.
All patients who underwent TR-PCI at our high-volume US medical center between 2004 and 2007 were included in this study. The primary end point was in-hospital adverse clinical outcomes between 6 and 24 hours postprocedure.
A total of 450 patients were included in this study (aged 59 +/- 11 years). Of these, 13% were female, 27% were diabetic, 6% had peripheral vascular disease, and 5% had chronic kidney disease. Procedural indications included stable angina (49%), unstable angina (31%), non-ST elevation myocardial infarction (NSTEMI) (17%), and ST elevation myocardial infarction (STEMI) (3%). All patients received an intra-arterial cocktail of heparin, verapamil, and nitroglycerin, and 13% of patients received glycoprotein IIb/IIIa inhibitors. Seven percent of patients had 3-vessel disease, 3% had bypass grafts stenoses, and 20% had class B(2)/C lesions. Procedural success rate was 96%. A total of 24 (5.3%) postprocedural complications were observed; however, none occurred between hours 6 to 24, the time differential between same-day and next-day discharge. Thirteen patients (2.9%) experienced significant complications within the first 6 hours (MI, urgent repeat revascularization, and ventricular tachycardia). Eleven (2.4%) spontaneously resolved minor access complications developed. There were 12 same-day discharges according to the operators' discretion; none required readmission.
Although a low incidence of complications did occur, none would have been impacted by same-day discharge. Those observed before 6 hours would have prevented early discharge, and those occurring after 24 hours would have been unaffected by routine next-day discharge. This observational study demonstrated the safety and feasibility for a prospective evaluation of ambulatory TR-PCI in an American practice setting.
尽管在欧洲和亚洲,非复杂性经桡动脉冠状动脉介入治疗(TR-PCI)后当日出院的安全性和成本效益已得到充分证实,但美国患者尚无此类数据。
本研究纳入了2004年至2007年期间在我们美国高容量医疗中心接受TR-PCI的所有患者。主要终点是术后6至24小时内的院内不良临床结局。
本研究共纳入450例患者(年龄59±11岁)。其中,13%为女性,27%为糖尿病患者,6%患有外周血管疾病,5%患有慢性肾脏病。手术指征包括稳定型心绞痛(49%)、不稳定型心绞痛(31%)、非ST段抬高型心肌梗死(NSTEMI)(17%)和ST段抬高型心肌梗死(STEMI)(3%)。所有患者均接受了肝素、维拉帕米和硝酸甘油的动脉内联合用药,13%的患者接受了糖蛋白IIb/IIIa抑制剂治疗。7%的患者患有三支血管病变,3%患有旁路移植血管狭窄,20%患有B(2)/C级病变。手术成功率为96%。共观察到24例(5.3%)术后并发症;然而,在6至24小时之间未发生并发症,这是当日出院和次日出院的时间差异。13例患者(2.9%)在最初6小时内出现严重并发症(心肌梗死、紧急重复血运重建和室性心动过速)。11例(2.4%)出现自发缓解的轻微穿刺部位并发症。根据操作者的判断,有12例患者当日出院;无一例需要再次入院。
尽管确实发生了低发生率的并发症,但当日出院不会对任何并发症产生影响。在6小时之前观察到的并发症会阻止早期出院,而在24小时之后发生的并发症则不会受到常规次日出院的影响。这项观察性研究证明了在美国实际情况下对门诊TR-PCI进行前瞻性评估的安全性和可行性。